Skip to Main Content

Paper Details

Correction: Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors.
1
2023
PSA, androgen, androgen receptor, docetaxel, metastatic hormone-sensitive prostate cancer, patients
Author NameAffiliation
Neeraj AgarwalHuntsman Cancer Institute, University of Utah
  • 1 - 1

Datasets

Release 1.2